BiotechTube

rhIGF-I/rhIGFBP-3 + placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myotonic Dystrophy Type 1

Conditions

Myotonic Dystrophy Type 1

Trial Timeline

Dec 1, 2007 → Dec 29, 2008

NCT ID
NCT00577577

About rhIGF-I/rhIGFBP-3 + placebo

rhIGF-I/rhIGFBP-3 + placebo is a phase 2 stage product being developed by Insmed for Myotonic Dystrophy Type 1. The current trial status is completed. This product is registered under clinical trial identifier NCT00577577. Target conditions include Myotonic Dystrophy Type 1.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00577577Phase 2Completed

Competing Products

16 competing products in Myotonic Dystrophy Type 1

See all competitors
ProductCompanyStageHype Score
TideglusibAMO PharmaPre-clinical
15
TideglusibAMO PharmaPhase 2
44
Tideglusib + PlaceboAMO PharmaPhase 2/3
57
TideglusibAMO PharmaPhase 2/3
57
VX-670Vertex PharmaceuticalsPhase 2
51
VX-670 + PlaceboVertex PharmaceuticalsPhase 1/2
40
SAR446268SanofiPhase 1/2
40
IONIS-DMPKRx + PlaceboIonis PharmaceuticalsPhase 1/2
38
Del-desiran (AOC 1001)Avidity BiosciencesPhase 3
74
ARO-DM1 Intravenous (IV) Infusion + Placebo Intravenous (IV) Infusion + ARO-DM1 subcutaneous (SC) injection + Placebo Subcutaneous (SC) InjectionArrowhead PharmaceuticalsPhase 1/2
38
DYNE-101 + PlaceboDyne TherapeuticsPhase 3
72
DYNE-101 + PlaceboDyne TherapeuticsPhase 1/2
36
Pitolisant Oral Tablet + Placebo oral tabletHarmony BiosciencesPhase 2
47
PGN-EDODM1PepGenPhase 2
44
PGN-EDODM1PepGenPhase 2
44
PGN-EDODM1 for infusionPepGenPhase 1
25

Other Products from Insmed

Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. + Tobramycin inhalation solution using a PARI LC® Plus nebulizer.Phase 3
74
Treprostinil Palmitil Inhalation Powder + PlaceboPhase 3
74
Treprostinil Palmitil Inhalation Powder + PlaceboPhase 3
74
ALIS + Azithromycin + Ethambutol + ELCPhase 3
74
LAI 590 mg + Multi-drug regimenPhase 3
74